The estimated Net Worth of Houte Hans Van is at least $1.97 millió dollars as of 26 August 2024. Mr Van owns over 20,000 units of Nurix Therapeutics stock worth over $736,918 and over the last 4 years he sold NRIX stock worth over $1,236,800.
Mr has made over 21 trades of the Nurix Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of NRIX stock worth $504,400 on 26 August 2024.
The largest trade he's ever made was exercising 68,333 units of Nurix Therapeutics stock on 31 May 2022 worth over $57,400. On average, Mr trades about 8,981 units every 49 days since 2021. As of 26 August 2024 he still owns at least 31,002 units of Nurix Therapeutics stock.
You can see the complete history of Mr Van stock trades at the bottom of the page.
Johannes Van Houte is the Chief Financial Officer at Nurix Therapeutics.
Mr Houte is 55, he's been the Chief Financial Officer of Nurix Therapeutics since . There are 5 older and 1 younger executives at Nurix Therapeutics. The oldest executive at Nurix Therapeutics, Inc. is Howard A. Simon J.D., Esq., SPHR, 62, who is the VP of Operations & Corp. Counsel.
Houte's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.
Over the last 4 years, insiders at Nurix Therapeutics have traded over $1,236,800 worth of Nurix Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall és Biomedical Innovation Maste.... On average, Nurix Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $116,806. The most recent stock trade was executed by Christine Ring on 3 September 2024, trading 9,050 units of NRIX stock currently worth $42,173.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Nurix Therapeutics executives and other stock owners filed with the SEC include: